Correction: SENP3 promotes tumor progression and is a novel prognostic biomarker in triple-negative breast cancer - Summary - MDSpire

Correction: SENP3 promotes tumor progression and is a novel prognostic biomarker in triple-negative breast cancer

  • By

  • Youzhi Zhu

  • Jiasheng Zhang

  • Liangfei Yu

  • Sunwang Xu

  • Ling Chen

  • Kunlin Wu

  • Lingjun Kong

  • Wei Lin

  • Jiajie Xue

  • Qingshui Wang

  • Yao Lin

  • Xiangjin Chen

  • May 12, 2026

  • 0 min

Share

Objective:

To correct the errors in the published figures regarding SENP3's role in tumor progression and its potential as a prognostic biomarker in triple-negative breast cancer, ensuring accurate data representation.

Key Findings:
  • SENP3 is implicated in tumor progression through specific molecular mechanisms.
  • SENP3 serves as a potential prognostic biomarker in triple-negative breast cancer, indicating patient outcomes.
Interpretation:

The correction ensures accurate representation of data related to SENP3's role in cancer progression.

Limitations:
  • The correction does not address any potential implications of the previous errors on the study's conclusions, which may affect the reliability of the findings.
Conclusion:

The article has been updated to reflect the correct data, reinforcing the significance of SENP3 in triple-negative breast cancer and highlighting the importance of accurate data representation in scientific research.

Original Source(s)

Correction: SENP3 promotes tumor progression and is a novel prognostic biomarker in triple-negative breast cancer

  • by Youzhi Zhu, Jiasheng Zhang, Liangfei Yu, Sunwang Xu, Ling Chen, Kunlin Wu, Lingjun Kong, Wei Lin, Jiajie Xue, Qingshui Wang, Yao Lin, Xiangjin Chen

  • May 12, 2026

Related Content

Case Report: Synovial sarcoma with diffuse myxoid stroma and complete absence of epithelial differentiation in the extremity

Immune biomarker landscape and fusion partner–phenotype associations in thoracic and head-and-neck NUT carcinoma

Data requirements of an informative, directive, and preventive mobile health application for gastric cancer